Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study - Atkins, M. B., Hodi, F. S., Thompson, J. A., McDermott, D. F., Hwu, W.-J., Lawrence, D. P., Dawson, N. A., Wong, D. J., Bhatia, S., James, M., Jain, L., Robey, S., Shu, X., Homet Moreno, B., Perini, R. F., Choueiri, T. K., Ribas, A. (The American Association for Cancer Research (AACR), 2018)
6234144
Keywords: WW-YZ